“…At present, this family comprises oxacyclododecindione ( 1 ), 4-dechloro-14-deoxyoxacyclododecindione ( 2 ), 14-deoxyoxacyclododecindione ( 3 ), and the recently reported 13-hydroxy-14-deoxyoxacyclododecindione ( 4 ) (Scheme ). Isolated from the imperfect fungus Exserohilum rostratum , these secondary metabolites ( 1 – 4 ) exhibit remarkable anti-inflammatory and antifibrotic properties, positioning them as a promising starting point for the development of drugs against chronic inflammation and fibrotic diseases like asthma, rheumatoid arthritis, and systemic lupus erythematosus or neoplastic diseases. ,, Prior research on these 12-membered macrolactones, including total syntheses, derivatization studies, and the establishment of initial structure–activity relationships through bioassays, has identified the enone moiety and the monochlorinated resorcinol backbone as crucial for their bioactivity, limiting the opportunities for modifications in these regions of the molecule. − To further investigate the potential of this compound family, current investigations consequently focus on the aliphatic backbone, to which molecular handles might be attached to facilitate the ongoing search for their biological target(s), which are still unknown at present. Our total synthesis of the proposed natural product 4 , isolated in 2018 by Shang and Lin et al, revealed mismatching spectroscopic data and required a reassignment of the initially proposed configuration .…”